POSITIVE SUBB2M IHC RESULTS FOR MELANOMA

- **Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ's SubB2M probe to aid in diagnosis of malignant melanoma in tissue samples**
- **Data from 144 tissue samples in this feasibility study demonstrated that SubB2M IHC detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions**
- **INOVIQ's SubB2M technology detects the pan-cancer biomarker Neu5Gc that is found at elevated levels in multiple human cancers**
- **SubB2M-based IHC applications represent a new product opportunity for SubB2M as an IHC reagent in the $1.9b IHC market**
- **INOVIQ to seek partners to sublicence the further development and commercialisation of SubB2M IHC tissue-based tests**

Melbourne, Australia, 26 July 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that a feasibility study to evaluate the use of SubB2M as an immunohistochemistry (tissue-based test) reagent to aid in discriminating between benign skin lesions, malignant and metastatic melanoma has been successfully completed.

In a study of 144 tissue samples (13 normal, 17 benign, 92 malignant and 22 metastatic), SubB2M staining scores were significantly greater in malignant and metastatic samples when compared to benign skin lesions ($p < 0.003$ and $p < 0.03$, respectively). Cells staining positive for SubB2M approached 100% in malignant and metastatic tissues. The cell staining was independently scored by Dr Ian Katz, Senior Pathologist at Southern Sun Pathology and Senior Lecturer at the School of Clinical Medicine, University of Queensland. The research-stage SubB2M IHC test has a sensitivity of 91% of detection of malignant and metastatic melanoma tissue samples.

The IHC program confirmed the presence of Neu5Gc (the binding target of SubB2M) in multiple tissue sections including breast, prostate, cervical, ovarian, colorectal and skin. These findings support INOVIQ's SubB2M diagnostics program developing blood tests for monitoring of breast, ovarian and other cancers.

CSO Dr Gregory Rice said: "The results obtained in this feasibility study support further optimization and validation of SubB2M as an IHC reagent, particularly as an aid in the diagnosis of malignant melanoma. Importantly, the detection of Neu5Gc in these cancer tissues is consistent with its role as a pan-cancer biomarker and further supports the development of INOVIQ's SubB2M-based blood tests for breast and ovarian cancers."

CEO Dr Leearne Hinch said: "INOVIQ remains focused on the development and commercialisation of its liquid biopsy pipeline of exosome and SubB2M-based blood tests for cancer and other diseases. Having successfully completed this SubB2M IHC feasibility study, the Company intends to seek interest from diagnostic companies and pathology laboratories to sublicense SubB2M for the development of IHC tissue-based tests."

The global immunohistochemistry market was valued at US$1.89 billion in 2021 and is expected to grow at a CAGR of 8.4% from 2022 to 2030. Hospitals and diagnostic laboratories dominated the market and accounted for the largest share of more than 70.5% of revenue. North America was the

largest geographic segment accounting for 38.5% share.[1] The skin cancer diagnostics market size is expected to be worth US$5.8b by 2028, with the melanoma segment representing US$2b.[2] In 2020, an estimated 324,635 people were diagnosed with melanoma globally and an estimated 57,043 people worldwide died from melanoma in the same year.[3]

SubB2M is an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc that is found at elevated levels in multiple human cancers. INOVIQ is developing SubB2M-based tests for multiple uses including monitoring of breast and ovarian cancers, and for a general health panel.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

[1] Grand View Research: Immunohistochemistry Market Size, Share & Trends Analysis Report By Product (Kits, Antibodies), By Application (Diagnostics, Drug Testing), By End-use (Research Institutes, Hospitals & Diagnostic Labs), And Segment Forecasts, 2022 – 2030
[2] Persistent Market Research
[3] https://www.wcrf.org/cancer-trends/skin-cancer-statistics/